Can Too Foundation is proud to announce our 2018 early career cancer researchers!
Can Too-ers have laced up their runners, thrown on a cossie, jumped on a bike and sung on stage to give these innovative researchers the opportunity they need to make a real difference to the research, prevention, care and control of
To read more about how we're investing in cancer research, click here.
2018 Early Career Cancer Researchers
Dr Angelica Merlot, University of Sydney, NSW
The spread of pancreatic cancer
Exploiting the ER Stress Pathways Against Pancreatic Cancer Metastasis
Dr Nicholas Fletcher, University of Queensland, QLD
New therapies for triple negative breast cancer
Dr Lauren Aoude, University of Queensland, QLD
Characteristics of melanoma
Genomics and biological correlates of
Dr Prahlad Raninga, QIMR Berghofer Medical Research Institute, QLD
New treatments for triple negative breast cancer
Targeting thioredoxin reductase 1 in novel combination therapies to treat triple negative breast cancer.
Dr Camille Guillerey, QIMR Berghofer Medical Research Institute
Developing preventative mechanisms for multiple myeloma
Blocking the inhibitory receptor TIGIT to restore immunity against multiple myeloma
Dr Su Yin Lim, Macquarie University, NSW
Immunotherapy for melanoma
Differential effects of MAPK inhibition on immune activity determine melanoma response
Dr Fernando de Souza Fonseca Guimaraes, Walter and Eliza Hall Institute of Medical Research, VIC
Immunotherapy for melanoma
Targeting suppressive TGF-beta to enhance innate lymphoid cell response against melanoma
Dr Sumit Sahni, University of Sydney, NSW
Therapies for pancreatic cancer
Molecular Role of the AMPK-Dependent Pathway in the Activity of Thiosemicarbazones Against Pancreatic Cancer
Dr Yuan Cao, University of Melbourne, VIC
Immunotherapy for breast cancer treatment
Targeting matrix metalloproteinase-12 (MMP12) promotes an immune response against breast cancer
Dr George Sharbeen, Lowy Cancer Research Centre University of NSW, NSW
Developing treatments for pancreatic cancer
MutY-Homolog is a Potential Therapeutic Target for Pancreatic Cancer
